Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLB1-016
- Development stage
- Preclinical
- Lead developer
- Huonslab
- Modality
- Peptides
01
Overview
HLB1-016 is a discovery-stage therapeutic candidate developed by Huonslab for the treatment of obesity. It functions as a long-acting GIPR (gastric inhibitory polypeptide receptor) antagonist. It is intended to be utilized in combination with a GLP-1R/-2R agonist. By blocking the GIP receptor, HLB1-016 aims to reduce energy storage and fat accumulation. This mechanism, combined with the activation of GLP-1R and GLP-2R, is designed to reduce food intake, enhance fat utilization, and improve insulin sensitivity, offering a novel approach to obesity management with the potential for high efficacy and minimal adverse effects.
02
Targets
GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on HLB1-016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLB1-016.